• Explore /
  • Poster
  • / Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.

Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.

Abstract Poster

Authors

null

Jonathan Forrest Anker

Icahn School of Medicine at Mount Sinai, New York, NY

Jonathan Forrest Anker , Mansi Saxena , Julia Kodysh , Timothy O'Donnell , Marcia Meseck , Olivia Hapanowicz , Scot Anthony Niglio , Hardik R. Shah , Yayoi Kinoshita , Rachel Brody , Alex Rubinsteyn , Robert P. Sebra , Nina Bhardwaj , Matt D. Galsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03359239

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 597)

DOI

10.1200/JCO.2024.42.4_suppl.597

Abstract #

597

Poster Bd #

G3

Abstract Disclosures

Similar Posters

First Author: Leonel Fernando Hernandez-Aya

First Author: Michael Bitzer

First Author: Guru P. Sonpavde

First Author: Ragisha Gopalakrishnan